ETF · SPDR
GXLV S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD
ISIN IE00BWBXM617London Stock Exchange: GXLVState Street Corp.
- Healthcare
- ETF
- ISA
- SIPP
- Accumulating
Latest close
LSE£44.38
on
- Ongoing charge
- 0.15% a year
- Fund size
- £501m
As of , at least 15 min delayed
At a glance
As of 13/11/2026, GXLV (S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD, ISIN IE00BWBXM617) closed at £44.38 on the London Stock Exchange. Its ongoing charge is 0.15% a year (about £15 on £10,000). Over the five years to 13/11/2026 its total return was +32.6%, or +3.5% after UK CPIH inflation.
Past returns
- 1 year to 13/11/2026
- +30.5%
- +25.9% after inflation (UK CPIH)
- 3 years to 13/11/2026
- +32.5%
- +19.7% after inflation (UK CPIH)
- 5 years to 13/11/2026
- +32.6%
- +3.5% after inflation (UK CPIH)
£1,000 put in five years ago would have been worth about £1,326 on 13/11/2026 — about £1,035 in today’s spending power, once price rises are taken out. Past performance is not a guide to future returns.
Returns: as reported (delayed data) and worked out from recorded daily closes. Inflation: UK CPIH, latest month published.
How we work it out:ReturnsReturns after inflationTotal returnReal returnCPIH
Calendar-year and 12-month returns
Calendar-year returns of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD in pounds (price, with income reinvested in the fund): 2023 −3.9%, 2024 +5.7%, 2025 +4.4%; 2026 to 13/11/2026 +25.0%. Returns of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +20.8%; to 30/09/2025: −5.1%; to 30/09/2024: +9.7%; to 30/09/2023: −2.9%.
| Year | Return | After inflation | Return shown as a bar |
|---|---|---|---|
| to | +25.0% | +21.0% | |
| to | +4.4% | +0.8% | |
| to | +5.7% | +2.1% | |
| −3.9% | −7.7% |
| 12 months to | Return | After inflation |
|---|---|---|
| from | +20.8% | +16.6% |
| from | −5.1% | −8.8% |
| from | +9.7% | +6.9% |
| from | −2.9% | −8.7% |
As of , inflation: UK CPIH
How we work it out:Calendar-year returnsWhat a calendar-year return isAccumulating and distributing
Risk: volatility and largest fall
Volatility (annualised)
14.6%over 3 years
| 1 year | 17.1% |
|---|---|
| 3 years | 14.6% |
Annualised from weekly returns. Higher means bumpier.
- Largest fall since April 2022
- −19.0%
- From to
- Lowest 12-month return
- −16.7%
- 12 months to
- Highest 12-month return
- +29.2%
- 12 months to
- Below its highest weekly close since April 2022
- 0.0%
- High of , latest
In words: Volatility of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD in pounds, annualised from weekly returns to 13/11/2026: 17.1% over 1 year, 14.6% over 3 years. Largest fall in the price of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD since April 2022, in pounds: −19.0% from 31/01/2025 to 23/05/2025. The lowest 12-month return of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD in pounds (price, with income reinvested in the fund) since April 2022 was −16.7% (12 months to 08/08/2025); the highest was +29.2% (12 months to 25/09/2026). On 13/11/2026 the price of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD was at its highest weekly close since April 2022, in pounds.
As of , price, with income reinvested in the fund
How we work it out:Risk figuresFallsVolatilityLargest fall
Charges compared with similar funds
- Ongoing charge
- 0.15%
- a year
- On £10,000
- £15
- a year, roughly
- Over five years
- £75
- of £10,000, before growth
- 2 charge less
- 1 the same
- 25 charge more
Ongoing charge of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD 0.15% a year. Compared on 14/11/2026, 25 of the 28 other healthcare funds charge more, 1 the same and 2 less (share classes counted once).
As of
A lower charge is not a promise of a higher return: what the fund holds matters more.
As of
Read more:Ongoing charge (OCF)OCF and TERFee dragHow charges add up
In plain English
SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD is an exchange-traded fund (ETF) from SPDR, launched in 2015.
It tracks the S&P Health Care Select Sector Daily Capped 35/20 Index.
You buy and sell it through a share-dealing account or platform during stock-market hours, like a share.
Its ongoing charge is 0.15% a year — about £15 a year on every £10,000 invested, taken from the fund's value rather than billed to you.
Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
Healthcare: Pharmaceutical, biotech and medical-equipment companies.
Terms:ETFIndex fundUCITSAccumulating or incomeShare classISIN
Key facts
- Ticker
- GXLV
- ISIN
- IE00BWBXM617
- Also listed as
- SXLV (London Stock Exchange, US dollars), ZPDH (Xetra, euros)
- Provider
- SPDR
- Tracks
- S&P Health Care Select Sector Daily Capped 35/20 Index
- Structure
- ETF
- An exchange-traded fund: bought and sold on the stock exchange through the day, like a share.
- Income
- Accumulating
- Income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
- Ongoing charge
- 0.15% a year · about £15 on £10,000
- Fund size
- £501m
- Launched
- Domicile
- Ireland
- UK reporting fund status
- Yes — on HMRC’s list of reporting funds (list of )
- Reporting fund since . What reporting fund status means
- Can usually be held in
- ISA and SIPP
- Check with your platform: each decides which funds it offers.
- Currency hedged
- No
- Price currency
- Pounds (GBP)
- Category
- Healthcare
Price chart
Over the last year, the closing price went from £35.62 on 14/11/2025 to £44.38 on 13/11/2026 (+24.6%). The lowest close shown was £32.68 on 08/05/2026 and the highest £44.38 on 13/11/2026.
One close a week. Before 18/09/2026 the closes are from the weekly price history for this listing; from then on, the closing prices we have recorded.
As of , at least 15 min delayed
Five years of prices, and after inflation
241 weekly closes, from 08/04/2022 to 13/11/2026. The same history in November 2026 pounds, adjusted with CPIH inflation.
Create a free account to see the 5-year price chart and the after-inflation chart
Sign-up takes an email address. There is no card to enter and nothing to pay.
How we work it out:Prices and returnsNAV and price
What it holds
- Holdings
- 60
- 61 reported in all
- Ten largest
- 60.5%
- of the whole fund
- Effective number of holdings
- 17
- As concentrated as this many equal-sized holdings (how it is worked out)
- Largest holding
- 16.3%
- Eli Lilly
Top 10 holdings
| Rank# | Holding | Weight as a percentage of the fund |
|---|---|---|
| 1 | Eli LillyLLYHealth CareUnited States | 16.32% |
| 2 | Johnson & JohnsonJNJHealth CareUnited States | 9.81% |
| 3 | AbbVieABBVHealth CareUnited States | 7.61% |
| 4 | MerckMRKHealth CareUnited States | 5.42% |
| 5 | UnitedHealth GroupUNHHealth CareUnited States | 5.31% |
| 6 | Thermo Fisher ScientificTMOHealth CareUnited States | 3.74% |
| 7 | AmgenAMGNHealth CareUnited States | 3.72% |
| 8 | Gilead SciencesGILDHealth CareUnited States | 3.10% |
| 9 | Abbott LaboratoriesABTHealth CareUnited States | 2.94% |
| 10 | PfizerPFEHealth CareUnited States | 2.54% |
As of , holdings as published
See the full portfolio
Every holding with search and filters, the whole breakdown by sector, country and type of asset, a map of the 60 largest and what changed since .
More of the portfolio
The fund publishes 61 holdings; the ten largest make up 60.5% of it. The fund's portfolio is also split by currency.
Create a free account to see the full holdings list and the currency, maturity and credit-quality breakdowns
Sign-up takes an email address. There is no card to enter and nothing to pay.
Holdings:Compare what it holds with another fundHoldings overlapHow overlap is measured
Risk and return in depth
Sharpe, Sortino and Calmar ratios
Sharpe, Sortino and Calmar ratios over 1 and 3 years, from weekly returns in pounds.
With a free accountRolling returns
The full range of 189 rolling 12-month returns since April 2022, in pounds, with how often they were above zero.
With a free accountLargest falls and recoveries
The 3 largest falls since April 2022, in pounds, with how many weeks each took to reach its low and to recover.
With a free account
Create a free account to see the risk ratios, every rolling return and each large fall and its recovery
Sign-up takes an email address. There is no card to enter and nothing to pay.
Moves compared with a similar fund
Correlation and beta of weekly returns in pounds against iShares Core S&P 500 UCITS ETF, over the three years to 13/11/2026 (154 weeks).
Pro
Pro — currently by invitation
Pro includes moves against a comparable fund
Pro is open by invitation while it is being built. There is nothing to buy. To ask about access, email [email protected].
Questions people ask
What is the ongoing charge of GXLV?
The ongoing charge of GXLV is 0.15% a year — about £15 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD 0.15% a year. Compared on 14/11/2026, 25 of the 28 other healthcare funds charge more, 1 the same and 2 less (share classes counted once).
What does GXLV track?
GXLV tracks the S&P Health Care Select Sector Daily Capped 35/20 Index.
Is GXLV accumulating or distributing?
GXLV is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
What is the ISIN of GXLV?
The ISIN of GXLV is IE00BWBXM617. An ISIN identifies one exact share class of a fund; GXLV is its ticker on the London Stock Exchange. The same share class is also listed as SXLV (London Stock Exchange, US dollars) and ZPDH (Xetra, euros).
What does GXLV hold?
As of 05/11/2026, GXLV holds 61 positions, according to its published holdings. The largest is Eli Lilly at 16.32% of the fund; the ten largest make up 60.5%. Its ten largest holdings are Eli Lilly (16.32%), Johnson & Johnson (9.81%), AbbVie (7.61%), Merck (5.42%), UnitedHealth Group (5.31%), Thermo Fisher Scientific (3.74%), Amgen (3.72%), Gilead Sciences (3.10%), Abbott Laboratories (2.94%) and Pfizer (2.54%).
What were GXLV’s returns in each of the last five years?
Calendar-year returns of GXLV in pounds (price, with income reinvested in the fund): 2023 −3.9%, 2024 +5.7%, 2025 +4.4%; 2026 to 13/11/2026 +25.0%. Past performance is not a guide to future returns.
How has GXLV done after inflation?
Over the five years to 13/11/2026 GXLV’s total return was +32.6%, or +3.5% after UK CPIH inflation. Past performance is not a guide to future returns.
Similar funds
- XWHSXtrackers MSCI World Health Care UCITS ETF0.25% a year · £3.4bn
- IHCUiShares S&P 500 Health Care Sector UCITS ETF0.15% a year · £2.7bn
- DRDRiShares Healthcare Innovation UCITS ETF0.40% a year · £1.3bn
- XSHCXtrackers MSCI USA Health Care UCITS ETF0.12% a year · £1.2bn
- BTEKiShares NASDAQ US Biotechnology UCITS ETF0.35% a year · £1.0bn
- CH5Amundi STOXX Europe 600 Healthcare UCITS ETF -Acc- Capitalisation0.30% a year · £833m
- ESIHiShares MSCIEurope Health Care Sector UCITS ETF AccumEUR0.18% a year · £798m
- 0DW6Amundi MSCI World Health Care UCITS ETF EUR ACC0.30% a year · £792m
Fund documents and methods
- Fund documents
- Fund page at State Street Global Advisors · Key investor information document (KIID) · Factsheet (links checked )
Methodology:ReturnsCategoriesAll methods
A machine-readable copy of this page: Markdown.